CCNI2 Inhibitors
CCNI2 inhibitors encompass a range of compounds designed to interfere with the protein's role in cell cycle progression. As a regulatory protein, CCNI2 is presumed to act through the activation of cyclin-dependent kinases (CDKs) which are essential for the transition through different phases of the cell cycle. The inhibitors work by targeting these kinase activities. For instance, certain small-molecule inhibitors act by selectively blocking the kinase activity of CDKs that are potentially activated by CCNI2, thus diminishing CCNI2's ability to drive cells from the G1 phase to the S phase, a critical transition in cell cycle progression. By impeding the formation of CCNI2-CDK complexes, these inhibitors indirectly hinder the role of CCNI2 incell cycle regulation. Moreover, some inhibitors are capable of influencing multiple CDKs, which could include those that interact with CCNI2, further broadening the scope of inhibition. These compounds may lead to a reduction in CCNI2's functional activity by preventing the phosphorylation events necessary for cell cycle progression.
The biochemical mechanisms of CCNI2 inhibition are complex and diverse, given the protein's interaction with various components of the cell cycle machinery. Some of the inhibitors exert their effects by binding to the ATP-binding sites of CDKs, thereby preventing ATP from binding and the subsequent phosphorylation of target proteins, which is essential for cell cycle progression. This ATP-competitive inhibition can effectively reduce the activity of CCNI2-associated CDK complexes. Other inhibitors may destabilize these complexes or alter their subcellular localization, further impeding CCNI2's ability to promote cell cycle advancement.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A selective inhibitor of CDK4 and CDK6, which are closely related to the CDKs that CCNI2 might activate. By inhibiting these kinases, this compound could reduce the activity of CCNI2-associated CDK complexes, leading to a decrease in CCNI2's ability to promote cell cycle progression. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Targets various CDKs including CDK2, which may interact with CCNI2. By inhibiting CDK2, roscovitine could impair the formation of CCNI2-CDK complexes that are critical for the G1/S phase transition, indirectly inhibiting CCNI2 function. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
A potent inhibitor of CDKs, flavopiridol could disrupt the activity of CDKs that partner with CCNI2, potentially impeding the cell cycle progression facilitated by CCNI2. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Selectively inhibits CDKs including CDK1, CDK2, and CDK5. If CCNI2 forms complexes with these CDKs, purvalanol A would inhibit their activity, thereby inhibiting the cell cycle regulatory functions of CCNI2. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
As an inhibitor of multiple CDKs, dinaciclib could hinder the kinase activity of CDK complexes that include CCNI2, indirectly reducing CCNI2's role in cell cycle regulation. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
A known inhibitor of CDKs, it could impair the kinase activity of CCNI2-associated CDKs, thereby blocking the cell cycle progression normally enhanced by CCNI2. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Inhibits CDK1 and CDK5 and could potentially inhibit other CDKs that CCNI2 might activate. This inhibition could prevent CCNI2 from exerting its effects on cell cycle progression. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Targets CDK1, CDK2, and CDK5, potentially affecting the kinase activity of CCNI2-associated CDK complexes and thus indirectly inhibiting CCNI2's function in the cell cycle. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
A selective inhibitor of CDK4 and CDK6. By inhibiting these kinases, ribociclib could reduce the activity of CCNI2-associated CDK complexes, leading to a decrease in CCNI2's ability to promote cell cycle progression. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
A potent inhibitor of CDK2, CDK7, and CDK9, which may interact with CCNI2. By inhibiting these kinases, SNS-032 could diminish the activity of CCNI2-associated CDK complexes, indirectly inhibiting CCNI2 activity. | ||||||